SUMMARY
SUMMARY
Clostridium difficile toxin B (269 kDa) is one of the causative agents of antibioticassociated diarrhea and pseudomembranous colitis. Toxin B acts in the cytosol of eukaryotic target cells, where it inactivates Rho GTPases by mono-glucosylation. The catalytic domain of toxin B is located at the N-terminus (amino acid residues 1-546). The C-terminal and the middle region of the toxin seem to be involved in receptor-binding and translocation. Here we studied, whether the full-length toxin or only a part of the holotoxin is translocated into the cytosol. Vero cells were treated with recombinant GST-toxin B, and thereafter, toxin B fragments were isolated by affinity precipitation of the GST-tagged protein from the cytosolic fraction of intoxicated cells. The toxin fragment (~65 kDa) was recognized by an antibody against the N-terminus of toxin B and was identified by MALDI-TOF mass spectrometry analysis as the catalytic domain of toxin B. The toxin fragment located in the cytosol possessed glucosyltransferase activity that could modify RhoA in vitro, but it was not able to intoxicate intact cells. After treatment of Vero cells with a radiolabeled fragment of toxin B (amino acid residues 547-2366), radioactivity was identified in the membrane fraction of Vero cells but not in the cytosolic fraction of Vero cells. Furthermore, analysis of cells by fluorescence microscopy revealed that the C-terminus of toxin B was located in endosomes, while the N-terminus was detected in the cytosol. Protease inhibitors, which were added to the cell medium, delayed intoxication of cells by toxin B and pH-dependent translocation of the toxin from the cell surface across the cell membrane. The data indicate that toxin B is proteolytically processed during its cellular uptake process.
INTRODUCTION

C.
1 difficile produces two large cytotoxins, toxin A (308 kDa) and toxin B (269 kDa).
These toxins are the major virulence factors of antibiotic-associated diarrhea and the causative agents of pseudomembranous colitis (1) (2) (3) (4) . In the cytosol of host cells, both toxins inactivate small GTPases of the Rho family, Rho, Rac and Cdc42, by mono-glucosylation at threonine37 in Rho and threonine35 in Rac and Cdc42 (5, 6) . Rho GTPases are involved in the organization of the actin cytoskeleton, and treatment of cultured cells with these toxins induces a redistribution of actin filaments leading to morphological alterations and, finally rounding-up of cells (7, 8) .
To reach their substrates in the cytosol, the catalytically active domain of the toxin must cross the cellular membrane. It has been proposed that toxin A and toxin B have a tripartite functional organization (see Fig. 1 ). The catalytic domain is located at the N-terminus of the toxin (9) , and the C-terminus is believed to bind to the cellular receptor (10) (11) (12) . The middle part of the protein harbors a hydrophobic region that is proposed to be involved in the translocation of the toxin across cellular membranes.
Over the past few years, some progress has been made in understanding the cellular uptake mechanism of the large clostridial cytotoxins. The toxins, or at least their enzymatic domains, translocate from early endosomal compartments into the cytosol (13, 14) . This step requires acidification of the endosomal lumen and can be blocked by the vesicular H + -ATPase inhibitor bafilomycin A1, which prevents acidification of endosomes (13) . This translocation of the toxin across endosomal membranes can be mimicked at the cell surface by a decrease 1 Abbreviations: C., Clostridium; CDB , catalytic domain of C. diffcile toxin B (amino acid in the pH of the culture medium. Extracellular acidification (pH 5.2) induces uptake of toxin B into the cytosol even in the presence of bafilomycin A1 (13, 14) . However, the mechanism of toxin translocation across membranes is still unclear. Moreover, it is not known whether the complete holotoxin or only its catalytic domain is transported into the cytosol. Recently, we reported that both full-length toxin B and its putative receptor binding/translocation domain (amino acid residues 547-2366, see Fig. 1 ), form pores in membranes of intact
Chinese Hamster Ovary cells (13) . This pore formation depends on an acidic pulse (5 min at pH 5.2). In addition, toxin B induces pH-dependent channels in artificial black lipid bilayers.
Most likely, the low pH of endosomes leads to a conformational change of toxin B, which is accompanied by membrane insertion and pore formation (13) . However, the role of the pores in translocation of the toxin or its catalytic domain is not clear.
Here, we cloned and expressed fragments of toxin B and used radiolabeling to study the translocation of the toxin into the cytosol of target cells. We found that during cellular uptake of toxin B, the binding/translocation domain (amino acid residues 547-2366) remained in endosomes of intoxicated cells and was not delivered into the cytosol. When cells were treated with the holotoxin and subsequently cytosolic and membrane fractions were separated, only an N-terminal, catalytically active fragment of toxin B, which showed in vitro glucosyltransferase activity, was detected in the cytosol. This polypeptide was identified as the catalytic domain of toxin B by immunoblot analysis, fluorescence microscopy and mass spectrometry.
plates at 37 °C and 5% CO 2 . Cells were routinely trypsinized and reseeded twice a week.
Astrocyte cultures were obtained from newborn Wistar rats (15) . After isolation of the cortices of rat brains, the surrounding meninges were removed prior to mincing. 
RESULTS
Identification of the enzyme domain of toxin B in the cytosol of Vero cells -So far, it is not
clear whether the full-length toxin B protein or only the N-terminal enzymatically active domain is translocated from endosomes into the cytosol. To identify the localization of the enzymatic domain of toxin B in intoxicated Vero cells, we chose three experimental approaches, which differed in the method to detect the enzyme activity and/or domain of the toxin. The scheme in Fig. 2 gives an overview of the experimental procedure. In all cases, cells were first incubated with toxin B until cytotoxic effects were observed by phase-contrast microscopy. Then, intoxicated cells were collected and lysed, and the cytosol and membranes were separated by ultracentrifugation. In the first approach, the two fractions were tested for enzyme activity in a glucosylation assay. Enzyme activity was detected mostly in the cytosolic fraction, but also to a lesser degree in the membrane fraction (Fig. 3A) . In the second approach, the cytosolic and the membrane fractions of intoxicated cells were tested for their ability to induce cytopathic effects on untreated Vero cells. As shown in Fig. 4 , only the membrane fraction was able to induce cytotoxic effects. We believe that the residual toxin B activity, which was found in the membrane fraction results from holotoxin, not from cleaved catalytically active fragment, because when this species was added to fresh cells, it was able to intoxicate these cells what suggests that the binding/translocation domain must be present in this protein. Maximal binding was observed after 90 min (Fig. 5A) (Fig. 5B) . (Fig. 6C) .
Intracellular localization of the catalytic domain
Protease inhibitor cocktail Complete™ blocks cytotoxic effects of toxin B and its
translocation across cell membranes -We studied processing of the toxin during the intoxication process by adding the protease inhibitor cocktail Complete™ to the cell medium.
In the presence of Complete™ intoxication of Vero cells by toxin B was dramatically delayed ( (Fig. 7A ). This finding suggests that the cleavage of toxin B occurs after its binding to the cell receptors.
Next, we tested whether the proteolytic cleavage of toxin B occurs at the cell surface or in acidified endosomes. Therefore, we used an well established experimental approach, which mimics the conditions of acidic endosomes. An acidic pulse induces the direct translocation of the toxin across cell membranes into the cytosol (13) . In these experiments, the inhibitor bafilomycin A1 blocks the v-type H + -ATPase of endosomes and thereby prevents acidification of endosomes and the physiological uptake pathway of toxin B. When cells were shifted for 5 min to acidic medium (pH 5.0) after binding of toxin B to the cell surface, cells rounded up within an further hour of incubation in neutral medium at 37 °C (Fig. 7B) . In contrast, no cell rounding was observed, when cells were exposed for 5 min to neutral medium. We tested the effect of Complete™ on the direct translocation of toxin B and found that it blocked intoxication of cells after exposure of the cells to acidic medium (Fig. 7B ).
This finding suggests that proteolytic cleavage of toxin B is essential for the delivery of active toxin into the cytosol.
Finally, it was tested whether the separated binding/translocation domain of toxin B was able to deliver the catalytically active domain into the cytosol of target cells. We incubated Vero cells with recombinantly expressed fragment CDB 547-2366 (10 µg/ml medium) together with CDB 1-546 (1 µg/ml). Neither addition of the single proteins nor the combination of both fragments in the cell medium induced any alterations in cell morphology (data not shown).
This observation indicates that both toxin domains must be linked during binding to cells.
DISCUSSION
Toxin B (269 kDa) is an exceptionally large bacterial protein toxin. As an exotoxin, it is released from the bacteria and targets eukaryotic cells. The toxin is taken up by target cells and mono-glucosylates Rho GTPases (Rho, Rac, Cdc42) in the cytosol. This cytotoxic action implicates that the toxin, or at least its catalytically domain, is delivered across cell membranes into the cytosol. Therefore, it is proposed that the toxin exhibits hydrophobic domains, that insert into membranes to allow translocation of the entire toxin or at least its active domain. It is well established that after binding to its cellular receptor the toxin is taken up via receptor-mediated endocytosis and that the active part translocates from early acidic endosomes into the cytosol (13) . However, the translocation mechanism for such an exceptionally large protein toxin is still enigmatic. Up to now, however, it was not shown, whether the holotoxin or only an enzymatically active part of toxin B reaches the cytosol. The successful expression of a GST-toxin B fusion protein in E. coli prompted us to address this important question and to study the fate and localization of toxin B during the uptake process.
In this report we demonstrate for the first time that the C. difficile toxin B is processed during cellular uptake and that the binding/translocation domain remains in early acidic endosomes, while the catalytically active N-terminal domain translocates from acidic endosomes into the cytosol of target cells.
Previous studies showed that the N-terminus of toxin B harbors the catalytically active domain of toxin B. This recombinant toxin fragment (CDB ) showed the same substrate (Rho, Rac, Cdc42) and co-substrate specificity as the holotoxin (9) and did not glucosylate further proteins from cell lysates. Moreover, the N-terminal domain of toxin B was sufficient to induce cytotoxic effects when delivered into the cytosol of cells by microinjection. This finding was confirmed using a chimeric toxin B-anthrax lethal toxin fusion protein (16, 17) .
These data indicate that for cytotoxicity of toxin B, delivery of the N-terminal domain into the cytosol is sufficient and translocation of the holotoxin is not required.
Here we present evidence that the N-terminus of toxin B, but not the middle or C-terminus, is translocated into the cytosol during the intoxication of cells. First, we showed that the cytosolic fraction obtained from intoxicated Vero cells contained the RhoA-glucosylation activity. Second, we were able to intoxicate naive cells with the membrane fraction of intoxicated cells, but not with the cytosolic fraction that contained the Rho-modifying activity. Third, we were able to isolate a peptide from the cytosolic fraction of toxin-treated cells by GST-affinity precipitation, which cross-reacted with an antibody directed against the N-terminus of toxin B. SDS-PAGE analysis revealed that this peptide migrated with an apparent molecular mass of ~65 kDa. Moreover, MALDI-TOF mass spectrometry analysis of the isolated ~65 kDa peptide showed that it contained exclusively amino acid sequences corresponding to the N-terminus of toxin B. It is important to note that the minimal Nterminal fragment of toxin B (amino acid residues 1-546), which could be expressed as an enzymatically active protein in E. coli (9) , has a molecular mass of 63.5 kDa. Therefore, we believe that the cleavage product of toxin B, which we detected in the cytosol of toxin-treated cells, corresponds very closely in size to the minimal active domain of toxin B reported recently (9) . Fourth, immunostaining of toxin-treated cells with antibodies directed against the N-terminus or against the middle and C-terminus of toxin B revealed a diffuse distribution of the N-terminus of toxin B probably in the cytosol, whereas the middle and C-terminus was exclusively detected in endosome-like structures, that colocalized with the early endosome marker Rab5. Finally, using protease inhibitors, we show that cleavage of toxin B is involved in the intoxication process.
Because we were not able to detect the middle or C-terminus of toxin B in the cytosol of (most likely in early endosomal vesicles) and not in the cytosol. Therefore, we suggest that this part of the toxin participates in the translocation of the catalytic domain from acidic endosomes into the cytosol; however, it does not freely enter the cytosol.
Taken together, our findings indicate that toxin B is processed during cellular uptake. The Nterminal, catalytically active domain is cleaved off and is delivered into the cytosol without the binding/translocation domain. This may explain earlier reports that toxin B needs processing in endosomal vesicles. When the holotoxin was delivered into the cytosol of cells via microinjection, cytotoxic effects were observed, but much higher amounts of toxin B were necessary to achieve these effects (18) . From these findings, the conclusion can be drawn that toxin B is also processed in the cytosol, but to a lesser extend than during "normal uptake" via acidic endosomes. So far, it is not entirely clear where the processing of toxin B occurs. Our studies show that the delivery across the cell membrane by mimicking the low pH of endosomes is blocked by protease inhibitors. Because we were not able to detect any autocatalytically cleavage of toxin B when it was treated for an extended time (1 h at 37 °C) at pH 7.5, 5.6 and 4.2 (not shown), we suggest that a host cell protease present in the endosome and/or at the cell membrane but not an autocatalytically processing is involved in toxin B cleavage.
The binding/translocation domain of toxin B includes the C-terminus of the protein, which contains units of repetitive oligopeptides (10) . The middle part of toxin B contains hydrophobic domains, which are thought to be essential for membrane insertion of the protein and for the translocation across the endosomal membranes. When this translocation domain is deleted, cytotoxicity is decreased by 4 orders of magnitude. It was shown by Qa'Dan and coworkers that toxin B undergoes pH-induced conformational changes and translocates across cell membranes under acidic conditions (14) . This is in line with our recent findings that acidic pH is absolutely essential for membrane insertion and pore formation of toxin B (13).
When cell-bound toxin B was exposed to an acidic impulse (5 min at pH 5.2), ion permeable pores were formed in membranes of intact cells. Pore formation was dependent on binding of the toxin to its cellular receptor prior to acidification of the extracellular medium. Moreover, the fragment CDB 547-2366 behaved similar to the holotoxin with respect to pore formation, suggesting that the binding/translocation domains are sufficient for this process (13) . 
